Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker DFTX
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 14,051 | $516.1K | — | Sep 25, 2026 | Form 4 ↗ 4 days later · 14,051 shares | Form 144 ↗ |
| Sep 25, 2026 | Brandi Roberts Officer | DFTX Definium Therapeutics, Inc. | 3,377 | $124.0K | — | Sep 25, 2026 | Form 4 ↗ 4 days later · 3,377 shares | Form 144 ↗ |
| Sep 25, 2026 | Matthew Thomas Wiley Officer | DFTX Definium Therapeutics, Inc. | 3,097 | $113.8K | — | Sep 25, 2026 | Form 4 ↗ 4 days later · 3,097 shares | Form 144 ↗ |
| Sep 25, 2026 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 10,853 | $398.6K | — | Sep 25, 2026 | Form 4 ↗ 4 days later · 10,853 shares | Form 144 ↗ |
| Sep 25, 2026 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 31,550 | $1.2M | — | Sep 25, 2026 | Form 4 ↗ 4 days later · 31,550 shares | Form 144 ↗ |
| Sep 3, 2026 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 19,023 | $718.1K | — | Sep 3, 2026 | Form 4 ↗ 1 day later · 19,023 shares | Form 144 ↗ |
| Jun 25, 2026 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 13,008 | $548.0K | — | Jun 25, 2026 | Form 4 ↗ 1 day later · 13,008 shares | Form 144 ↗ |
| Jun 25, 2026 | Matthew Thomas Wiley Officer | DFTX Definium Therapeutics, Inc. | 2,867 | $120.8K | — | Jun 25, 2026 | Form 4 ↗ 1 day later · 2,867 shares | Form 144 ↗ |
| Jun 25, 2026 | Brandi Roberts Officer | DFTX Definium Therapeutics, Inc. | 3,013 | $126.9K | — | Jun 25, 2026 | Form 4 ↗ 1 day later · 3,013 shares | Form 144 ↗ |
| Jun 25, 2026 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 10,035 | $422.8K | — | Jun 25, 2026 | Form 4 ↗ 1 day later · 10,035 shares | Form 144 ↗ |
| Jun 25, 2026 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 29,208 | $1.2M | — | Jun 25, 2026 | Form 4 ↗ 1 day later · 29,208 shares | Form 144 ↗ |
| Mar 25, 2026 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 24,431 | $451.2K | — | Mar 25, 2026 | Form 4 ↗ 1 day later · 24,431 shares | Form 144 ↗ |
| Mar 25, 2026 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 8,018 | $148.1K | — | Mar 25, 2026 | Form 4 ↗ 1 day later · 8,018 shares | Form 144 ↗ |
| Mar 25, 2026 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 10,702 | $197.7K | — | Mar 25, 2026 | Form 4 ↗ 1 day later · 10,702 shares | Form 144 ↗ |
| Dec 29, 2025 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 5,600 | $73.6K | 10b5-1 | Dec 26, 2025 | Form 4 ↗ 87 days later · 8,018 shares | Form 144 ↗ |
| Dec 29, 2025 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 11,276 | $148.2K | 10b5-1 | Dec 26, 2025 | Form 4 ↗ 87 days later · 10,702 shares | Form 144 ↗ |
| Dec 29, 2025 | Robert Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 25,791 | $339.1K | 10b5-1 | Dec 26, 2025 | Form 4 ↗ 87 days later · 24,431 shares | Form 144 ↗ |
| Sep 25, 2025 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 11,278 | $110.2K | — | Sep 25, 2025 | Form 4 ↗ 1 day later · 11,278 shares | Form 144 ↗ |
| Sep 25, 2025 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 7,704 | $75.3K | — | Sep 25, 2025 | Form 4 ↗ 1 day later · 7,704 shares | Form 144 ↗ |
| Sep 25, 2025 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 25,797 | $252.1K | — | Sep 25, 2025 | Form 4 ↗ 1 day later · 25,797 shares | Form 144 ↗ |
| Jun 25, 2025 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 7,848 | $53.4K | — | Jun 25, 2025 | Form 4 ↗ 1 day later · 7,848 shares | Form 144 ↗ |
| Jun 25, 2025 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 11,491 | $78.2K | — | Jun 25, 2025 | Form 4 ↗ 1 day later · 11,491 shares | Form 144 ↗ |
| Jun 25, 2025 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 26,491 | $180.2K | — | Jun 25, 2025 | Form 4 ↗ 1 day later · 26,491 shares | Form 144 ↗ |
| Mar 25, 2025 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 6,576 | $44.3K | — | Mar 25, 2025 | Form 4 ↗ 1 day later · 6,576 shares | Form 144 ↗ |
| Mar 25, 2025 | Carrie Liao Officer | DFTX Definium Therapeutics, Inc. | 2,347 | $15.8K | — | Mar 25, 2025 | Form 4 ↗ 1 day later · 2,347 shares | Form 144 ↗ |
| Mar 25, 2025 | Robert B Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 21,208 | $142.9K | — | Mar 25, 2025 | Form 4 ↗ 1 day later · 21,208 shares | Form 144 ↗ |
| Mar 25, 2025 | Daniel Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,836 | $46.1K | — | Mar 25, 2025 | Form 4 ↗ 1 day later · 6,836 shares | Form 144 ↗ |
| Dec 26, 2024 | Robert B Barrow Officer | DFTX Definium Therapeutics, Inc. | 19,106 | $142.0K | — | Dec 26, 2024 | Form 4 ↗ 1 day later · 19,106 shares | Form 144 ↗ |
| Dec 26, 2024 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 4,519 | $33.6K | — | Dec 26, 2024 | Form 4 ↗ 1 day later · 4,519 shares | Form 144 ↗ |
| Dec 26, 2024 | Dan Rollings Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,643 | $49.4K | — | Dec 26, 2024 | Form 4 ↗ 1 day later · 6,643 shares | Form 144 ↗ |
| Dec 26, 2024 | Carrie Liao Officer | DFTX Definium Therapeutics, Inc. | 2,273 | $16.9K | — | Dec 26, 2024 | Form 4 ↗ 1 day later · 2,273 shares | Form 144 ↗ |
| Sep 25, 2024 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 4,430 | $26.5K | 10b5-1 | Sep 25, 2024 | — | Form 144 ↗ |
| Sep 25, 2024 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,871 | $41.1K | 10b5-1 | Sep 25, 2024 | — | Form 144 ↗ |
| Sep 25, 2024 | Robert Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 19,771 | $118.2K | 10b5-1 | Sep 25, 2024 | — | Form 144 ↗ |
| Jun 25, 2024 | Mark Sullivan Officer | DFTX Definium Therapeutics, Inc. | 17,854 | $129.0K | 10b5-1 | Jun 25, 2024 | — | Form 144 ↗ |
| Jun 25, 2024 | Robert Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 15,659 | $113.1K | 10b5-1 | Jun 25, 2024 | — | Form 144 ↗ |
| Jun 25, 2024 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,925 | $50.0K | 10b5-1 | Jun 25, 2024 | — | Form 144 ↗ |
| Mar 25, 2024 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,578 | $62.5K | 10b5-1 | Mar 25, 2024 | — | Form 144 ↗ |
| Mar 25, 2024 | Robert Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 16,519 | $156.9K | 10b5-1 | Mar 25, 2024 | — | Form 144 ↗ |
| Mar 1, 2024 | Wiedmann Lindsey Roon Chief Legal & Sustainability Officer | DFTX Definium Therapeutics, Inc. | 10,000 | $39.4K | — | Mar 1, 2024 | — | Form 144 ↗ |
| Dec 26, 2023 | Robert Barrow Officer, Director | DFTX Definium Therapeutics, Inc. | 13,237 | $48.1K | 10b5-1 | Dec 26, 2023 | — | Form 144 ↗ |
| Dec 26, 2023 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 6,774 | $24.6K | 10b5-1 | Dec 26, 2023 | — | Form 144 ↗ |
| Dec 26, 2023 | Schond L. Greenway Officer | DFTX Definium Therapeutics, Inc. | 5,652 | $20.5K | 10b5-1 | Dec 26, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Robert Barrow Officer | DFTX Definium Therapeutics, Inc. | 5,268 | $18.8K | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Robert Barrow Officer | DFTX Definium Therapeutics, Inc. | 8,231 | $29.5K | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Schond L. Greenway Officer | DFTX Definium Therapeutics, Inc. | 1,908 | $6,804 | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Schond L. Greenway Officer | DFTX Definium Therapeutics, Inc. | 3,854 | $13.8K | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 3,678 | $13.1K | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Sep 25, 2023 | Dan Karlin Officer | DFTX Definium Therapeutics, Inc. | 3,240 | $11.6K | 10b5-1 | Sep 25, 2023 | — | Form 144 ↗ |
| Aug 28, 2023 | Schond L. Greenway Officer | DFTX Definium Therapeutics, Inc. | 20,000 | $77.2K | — | Aug 25, 2023 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances